Amylyx Pharmaceuticals, Inc.
Price
Overview
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
History & business model
This section is waiting to be written.
InvestWiki is community-edited. Contribute a plain-English history of Amylyx Pharmaceuticals, Inc., its business model, key products, and controversies.